Compare MGYR & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGYR | GANX |
|---|---|---|
| Founded | 1922 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.1M | 78.2M |
| IPO Year | 2021 | 2021 |
| Metric | MGYR | GANX |
|---|---|---|
| Price | $17.66 | $2.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 3.1K | ★ 552.8K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | 26.83 | ★ 31.46 |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.75 | $1.41 |
| 52 Week High | $20.00 | $4.34 |
| Indicator | MGYR | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 53.96 |
| Support Level | $16.83 | $1.55 |
| Resistance Level | $17.91 | $2.40 |
| Average True Range (ATR) | 0.41 | 0.14 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 67.62 | 84.46 |
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.